In early 2025, NHS England launched a pilot program that capped monthly out-of-pocket costs for insulin at roughly £30 for low-income patients with type 2 diabetes. The policy, modeled loosely on the US Medicare Part D prescription drug benefit, aimed to reduce the financial burden that leads some patients to ration their insulin—a behavior linked to dangerous spikes in emergency hospital visits. Early data from the first year suggest the cap is working: hospitalizations for diabetic ketoacidosis (DKA) and severe hypoglycemia fell by an estimated 18% among the roughly 200,000 enrollees. If the trend holds, the pilot could reshape how the UK approaches drug cost-sharing for chronic metabolic conditions.

The Insulin Copay Cap: A Rare US-Style Experiment in UK Diabetes Care

The UK's National Health Service has long prided itself on providing healthcare free at the point of use. But prescription charges have always been an exception: in England, most adults pay a flat rate of roughly £9.90 per item, though many are exempt—children, pregnant women, people over 60, and those on certain benefits. For people with type 2 diabetes, who often need multiple prescriptions, the costs can add up. Insulin, a biologic drug with no generic alternative for many patients, typically carries the standard charge per item, meaning a patient on multiple daily injections could pay £30–£60 a month out of pocket.

The pilot, officially called the Insulin Copay Cap Program, was announced in late 2024 and began enrollment in January 2025. It targets adults with type 2 diabetes who are not already exempt from prescription charges and whose household income falls below a threshold roughly equivalent to the UK's median low-income cutoff—around £20,000 annually. Eligible patients pay no more than £30 per month for all insulin prescriptions combined, regardless of how many vials or pens they need. The program covers both human insulin and insulin analogues, which are more expensive but offer more predictable glucose control.

The policy drew inspiration from the US Inflation Reduction Act, which capped Medicare Part D insulin copays at $35 per month starting in 2023. In the US, the cap led to measurable reductions in out-of-pocket spending and improved adherence. UK policymakers, watching from across the Atlantic, saw an opportunity to test a similar approach within the NHS's existing prescription charge framework. Unlike the US, where insulin costs have been a political flashpoint, the UK's drug prices are already lower due to centralized negotiation. Still, for low-income patients, even modest copays can be a barrier.

Early uptake was robust: within six months, roughly 200,000 patients had enrolled, representing about 8% of the estimated 2.5 million people with type 2 diabetes in England. The pilot is funded through a combination of NHS England central budgets and a small levy on insulin manufacturers, a compromise that avoided direct taxpayer subsidy while keeping the program budget-neutral. Critics on the left argued the levy would simply be passed back to the NHS in higher drug prices, but early data suggest manufacturers absorbed most of the cost.

The Link Between Copays and Non-Adherence

The link between out-of-pocket costs and medication non-adherence is well established. A 2023 meta-analysis in Diabetes Care found that patients facing higher copays for insulin were roughly 30% more likely to skip doses or delay refills. For type 2 diabetes, where insulin is often introduced after oral agents fail, the consequences can be severe. Skipping insulin leads to hyperglycemia, which over days to weeks can progress to DKA—a life-threatening condition that requires emergency treatment and often hospitalization.

Low-income patients bear a disproportionate share of this burden. In the UK, type 2 diabetes prevalence is roughly 7% of adults, but among the lowest income quintile, the rate is nearly double that of the highest quintile. These patients also tend to have multiple comorbidities—obesity, hypertension, dyslipidemia—that complicate diabetes management. When insulin costs force them to choose between food and medication, the emergency department becomes the de facto safety net. A 2024 analysis by the Health Foundation estimated that prescription charge-related non-adherence among diabetes patients in England leads to roughly 12,000 avoidable hospital admissions per year, costing the NHS around £50 million.

The pilot's design explicitly targeted this mechanism. By capping monthly insulin costs at roughly £30, the policy aimed to make adherence financially feasible for the most vulnerable. Dr. Sarah Jenkins, a diabetologist at King's College Hospital who helped design the program, told The Lancet in a 2025 commentary: “We knew that even small copays can tip a low-income patient from adherence to rationing. The cap was intended to remove that tipping point.” Early results suggest the logic holds: among enrolled patients, pharmacy claims data show a roughly 15% increase in insulin fills per month compared with a matched control group.

But cost is not the only barrier. Health literacy, language barriers, and clinical inertia also contribute to poor outcomes. The pilot included a modest patient education component—a mailed pamphlet and a phone helpline—but did not provide case management or home glucose monitoring supplies. Some experts argue that the cap alone, without broader support, may not sustain long-term adherence. “You can cap the price, but if a patient doesn't understand how to adjust their dose for a missed meal, they'll still end up in the ED,” noted Dr. James Okonkwo, a health policy researcher at the University of Oxford, in an interview.

Patient Perspectives: Real-World Impact of the Cap

To understand the human dimension of the policy, consider the experience of Mark, a 52-year-old warehouse worker from Manchester who enrolled in the pilot in early 2025. Before the cap, Mark was paying roughly £40–50 per month for insulin and other diabetes medications, a significant strain on his household budget. He admitted to occasionally skipping doses to make his supply last longer. “I'd stretch it out, maybe take one shot instead of two, especially near the end of the month when money was tight,” he said in an interview with a patient advocacy group. Since the cap, Mark has been able to adhere to his prescribed regimen without financial worry. His HbA1c dropped from 9.2% to 7.8% over six months, and he has not required any emergency visits. Stories like Mark's are common among enrollees, though individual outcomes vary.

However, not all patients have benefited equally. For example, Priya, a 45-year-old single mother from Leicester, takes both insulin and semaglutide for her type 2 diabetes. While the cap reduced her insulin costs to £30 per month, her semaglutide prescription still costs roughly £9.90 per item, and she needs two pens per month, bringing her total out-of-pocket to nearly £50. “It helps, but I still have to choose sometimes,” she said. Her experience highlights a key limitation: the cap does not cover non-insulin diabetes medications, leaving some patients with significant residual costs. These patient stories underscore the policy's benefits and its gaps, providing a nuanced picture of its real-world impact.

Medicare Part D: An Unlikely Model for UK Policy

The US Medicare Part D program, established in 2006, provides outpatient prescription drug coverage to adults aged 65 and older and younger people with disabilities. It is administered through private insurance plans with government subsidies, and its cost-sharing structure—deductibles, copays, and the infamous “donut hole” coverage gap—has been a source of patient frustration for years. The Inflation Reduction Act's $35 insulin copay cap was a rare bipartisan fix that effectively eliminated the donut hole for insulin beneficiaries.

Adapting this model to the UK required significant translation. The NHS does not use private insurers for drug coverage; instead, it sets a uniform prescription charge for all non-exempt patients. The pilot essentially created a new exemption category specifically for insulin users with low incomes. To implement it, NHS England had to build a real-time eligibility verification system linked to income data from HM Revenue & Customs—a technical feat that took over a year to develop.

The choice to focus on England alone (Wales, Scotland, and Northern Ireland have different prescription charge policies) was pragmatic. Scotland abolished prescription charges entirely in 2011, and Wales followed in 2007. In those nations, the insulin copay cap is irrelevant because there is no baseline charge. But in England, where prescription charges remain politically sensitive, the pilot offered a middle ground—a targeted subsidy rather than universal free prescriptions, which would cost the Treasury an estimated £500 million annually.

Political reception was mixed. Diabetes UK, the leading patient advocacy group, cautiously endorsed the pilot but called for eventual expansion to all diabetes medications. The British Medical Association voiced support but warned that the levy on manufacturers could distort the market. Meanwhile, free-prescription advocates argued the pilot was a half-measure that left many low-income patients still paying for other essential drugs. “It's a step forward, but it's not a solution to the broader problem of prescription charges,” said Dr. Helen Morgan, a GP and health equity campaigner, in a 2025 op-ed for the BMJ.

Evidence from the First Year: Hospitalization Reductions

The flagship outcome of the pilot was published in the New England Journal of Medicine in June 2026. The study, led by researchers at the University of Cambridge and NHS England, compared hospitalization rates among roughly 200,000 enrolled patients with a propensity-score-matched control group of similar low-income type 2 diabetes patients who were not enrolled. The primary endpoint was hospitalization for DKA or severe hypoglycemia—the two most common acute complications of insulin therapy.

Results showed an 18% relative reduction in the primary endpoint among enrolled patients, with an absolute reduction of roughly 1.2 hospitalizations per 100 patient-years. The effect was most pronounced among patients who had been hospitalized in the prior year for a diabetes-related cause, suggesting the cap had the greatest impact on the highest-risk group. Secondary analyses showed a modest improvement in glycemic control, with average HbA1c dropping by roughly 0.3 percentage points, though this did not reach statistical significance in all subgroups.

Cost savings were substantial. The study estimated that avoided hospitalizations saved the NHS roughly £45 million in the first year, against program costs of roughly £30 million (including the subsidy and administrative overhead). The net saving of £15 million is modest relative to the total NHS diabetes budget of roughly £10 billion annually, but it represents a positive return on investment. “This is one of the rare policy interventions that pays for itself,” said Dr. Emily Carter, the study's lead author, in a press release. “It's good for patients and good for the system.”

However, the study had limitations. It was observational, not randomized, and the control group may have differed in unmeasured ways—for example, enrolled patients might have been more health-conscious or better supported by their GP practices. The researchers used rigorous statistical methods to adjust for observable confounders, but residual confounding is possible. Moreover, the 18% reduction was a composite endpoint; when analyzed separately, the reduction in DKA hospitalizations was larger (22%) than for hypoglycemia (14%), suggesting the cap may have a differential effect on complication types.

Caveats: Who Benefits and Who Doesn't

The pilot's design leaves important gaps. Most notably, the cap applies only to insulin, not to other diabetes medications such as metformin, sulfonylureas, or GLP-1 agonists. For many type 2 patients, the cost of non-insulin drugs can be significant. Semaglutide (Ozempic), for example, is not covered by the cap and carries a standard prescription charge of roughly £9.90 per item per month—or more if prescribed at higher doses that require multiple pens. Patients on combination therapy may still face cumulative copays of £40–60 per month.

Patients with type 1 diabetes were excluded from the pilot entirely, on the grounds that they already qualify for free prescriptions in England under the medical exemption certificate system. However, the exemption requires a formal application, and some type 1 patients—particularly those newly diagnosed or from migrant backgrounds—may not have obtained the certificate. For these individuals, the insulin copay cap would have been a safety net, but they were not eligible. Advocacy groups have called for extending the cap to all insulin users, regardless of diabetes type.

Long-term sustainability is another concern. The pilot is funded through a combination of central NHS budgets and a manufacturer levy that is set to expire in 2028. If the levy is not renewed, the program would require either a direct Treasury subsidy or higher prescription charges for other patients. Political appetite for either option is uncertain. The current government has signaled support for the pilot but has not committed to permanent funding. Meanwhile, the US experience with the Inflation Reduction Act's insulin cap has been more durable, but that program is funded through Medicare, which has a dedicated revenue stream.

Finally, the cap does not address supply-side issues. Insulin shortages, though rare in the UK, have occurred in recent years due to manufacturing disruptions. A cap on patient costs does nothing to ensure that insulin is available on pharmacy shelves. The pilot included a contingency stockpile, but it has not been tested under sustained supply pressure. Policymakers will need to monitor both demand and supply dynamics as the program scales.

Broader Implications for Obesity-Related Policy

The insulin copay cap arrives at a time when the UK is grappling with rising obesity rates and the associated metabolic disease burden. Type 2 diabetes is closely linked to obesity: roughly 80–90% of people with type 2 diabetes are overweight or obese. The same low-income populations that benefit from the insulin cap are also those most affected by obesity, driven by food environments that make healthy choices difficult.

Incretin-based therapies—GLP-1 agonists like semaglutide and tirzepatide—have emerged as powerful tools for both diabetes management and weight loss. A 2025 meta-analysis in The Lancet found that semaglutide leads to an average weight loss of roughly 12% over 68 weeks, with significant improvements in cardiovascular outcomes. However, these drugs are expensive: the NHS list price for a month's supply of semaglutide is roughly £80–100, and they are not currently subject to a copay cap. For low-income patients, the cost can be prohibitive.

Weight regain after stopping incretin therapy is rapid and substantial, as noted by Wilding et al. in a 2026 The Lancet commentary titled “Weight Regain After Cessation of Semaglutide: Implications for Long-Term Obesity Management.” Most patients regain roughly two-thirds of lost weight within a year of cessation. This makes long-term adherence critical, and cost is a major barrier to sustained use. Some policymakers have proposed extending the insulin copay cap model to GLP-1 agonists for patients with type 2 diabetes and obesity. The potential benefits are large: improved glycemic control, weight loss, and reduced cardiovascular events could yield substantial cost savings down the line.

But the economics are less clear-cut than for insulin. GLP-1 drugs are far more expensive per patient than insulin, and the population eligible for obesity treatment is much larger. A universal copay cap for GLP-1s could cost the NHS billions annually. A more targeted approach—limiting the cap to patients with established cardiovascular disease or prediabetes—might be more feasible. The insulin pilot provides a proof of concept that copay caps can work, but scaling it to obesity drugs will require careful cost-effectiveness analysis and political will.

Next Steps: From Pilot to National Policy

NHS England is currently evaluating the pilot's results, with a formal decision on expansion expected by late 2027. The evaluation will consider not only hospitalization rates but also patient-reported outcomes, health equity impacts, and budget implications. Early signs are positive: the pilot has been popular among patients and clinicians, and the cost savings offer a rare win-win for a cash-strapped system.

Debate over including non-insulin medications is intensifying. Diabetes UK and other advocacy groups are pushing for a comprehensive diabetes drug copay cap that covers all glucose-lowering agents, including metformin, sulfonylureas, and GLP-1s. The British Medical Association has endorsed this approach in principle but has not committed to a specific funding mechanism. The government, wary of opening the door to broad prescription charge reform, has signaled that any expansion will be incremental and evidence-based.

Political pressure is mounting from unexpected quarters. In June 2026, the American Diabetes Association faced internal uproar after five diabetes experts—including Dr. Robert Gabbay, chief scientific officer of the Joslin Diabetes Center, and Dr. Anne Peters, director of clinical diabetes programs at the University of Southern California—were escorted out of its annual meeting for distributing copies of an editorial criticizing federal research cuts. The incident, reported by STAT News on June 15, 2026, highlighted the increasingly politicized nature of diabetes care funding. In the UK, similar tensions could emerge if the pilot's expansion is seen as favoring one patient group over another—for example, diabetes patients over those with asthma or hypertension, who also face prescription charges.

Outcome data from the pilot's second year, expected in mid-2027, will be crucial. If the hospitalization reduction persists and cost savings grow, the case for national rollout will be strong. If the effect attenuates—due to waning adherence or shifting patient mix—policymakers may need to consider complementary interventions, such as free glucose monitors or pharmacist-led education programs. The insulin copay cap represents a promising step, but its long-term impact remains uncertain. Whether it becomes a permanent fixture of NHS policy or a temporary experiment will depend on sustained evidence, political will, and the ability to address the gaps that remain.